TH2141A - - Google Patents
Info
- Publication number
- TH2141A TH2141A TH8401000321A TH8401000321A TH2141A TH 2141 A TH2141 A TH 2141A TH 8401000321 A TH8401000321 A TH 8401000321A TH 8401000321 A TH8401000321 A TH 8401000321A TH 2141 A TH2141 A TH 2141A
- Authority
- TH
- Thailand
- Prior art keywords
- hepatitis
- type
- preparation according
- gel
- preparation
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 claims abstract 11
- 208000002672 hepatitis B Diseases 0.000 claims abstract 9
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims abstract 7
- 229910052782 aluminium Inorganic materials 0.000 claims abstract 7
- 239000003381 stabilizer Substances 0.000 claims abstract 7
- 239000000427 antigen Substances 0.000 claims abstract 6
- 102000036639 antigens Human genes 0.000 claims abstract 6
- 108091007433 antigens Proteins 0.000 claims abstract 6
- 241000700605 Viruses Species 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims abstract 3
- 238000004108 freeze drying Methods 0.000 claims 6
- 239000000499 gel Substances 0.000 claims 6
- 150000001720 carbohydrates Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 229930091371 Fructose Natural products 0.000 claims 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 2
- 239000005715 Fructose Substances 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 2
- 229930182830 galactose Natural products 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 claims 2
- 235000013923 monosodium glutamate Nutrition 0.000 claims 2
- 239000004223 monosodium glutamate Substances 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 235000010356 sorbitol Nutrition 0.000 claims 2
- 239000000811 xylitol Substances 0.000 claims 2
- 235000010447 xylitol Nutrition 0.000 claims 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 2
- 229960002675 xylitol Drugs 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 241000566113 Branta sandvicensis Species 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 claims 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000009697 arginine Nutrition 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- -1 sacchalose Chemical compound 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 abstract 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Abstract
การเตรียมวัคซีนสำหรับตับอักเสบชนิด B ด้วยวิธีไลโอฟิไลส์,ซึ่งประกอบด้วยสารที่ทำให้เสถียรและแอนทีเจนสำหรับตับอักเสบชนิด B ที่มีไวรัสอยู่ที่ผิว ซึ่งได้ทำให้บริสุทธิ์,ไม่ว่องไว ได้ถูกดูดซับอยู่อะลูมินัมเจล ซึ่งเตรียมได้โดยการเติมอะลูมินัมเจลและสารที่ทำให้เสถียรลงในแอนทิเจนสำหรับตับอักเสบชนิด B ที่มีไวรัสอยู่ที่ผิวและทำไลโอฟิไลส์ของผสมนี้ การเตรียมด้วยวิธีทำไลโอฟิไลส์ดังกล่าวนี้เสถียรสามารถเก็บเอาไว้ในช่วงเวลายาวโดยปราศจากการสูญเสียกำลังแรงของแอนทิเจนและใช้ประโยชน์สำหรับป้องกันการติดเชื้อโรคไวรัสสำหรับตับอักเสบชนิด B สิทธิบัตรยา A lyophilized hepatitis B vaccine preparation, containing stabilizers and antigens for hepatitis B with the virus on the surface. Purified Has been absorbed in the aluminum gel It was prepared by adding aluminum gel and stabilizer to the antigen for viral hepatitis B type on the surface and by lyophilizing the mixture. This lyophilized preparation is stable, can be stored over a long period of time without antigen depletion and is used for the prevention of viral infection for hepatitis B type. Drug patent
Claims (9)
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TH2141A true TH2141A (en) | 1985-01-02 |
| TH3890B TH3890B (en) | 1994-07-29 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR850002277A (en) | Lyophilized hepatitis B wax composition and preparation method thereof | |
| Atkins | Pathogenesis of fever | |
| JP3228512B2 (en) | Compositions and methods for treating hepatitis C | |
| ES2224646T3 (en) | PREPARATION OF A STABILIZED HERPEVIRUS. | |
| CA2272245A1 (en) | Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies | |
| JPH046689B2 (en) | ||
| US4537769A (en) | Stabilization of influenza virus vaccine | |
| US8216588B2 (en) | Lyophilized preparation comprising influenza vaccine, and method for preparation thereof | |
| US11878054B2 (en) | VLP stabilized vaccine compositions | |
| JP2001524533A (en) | Transdermal delivery of particulate vaccine compositions | |
| EP0135841A2 (en) | Herpes simplex virus subunit vaccine | |
| RU2014151424A (en) | THERMOSTABLE VACCINE COMPOSITIONS | |
| KR900015749A (en) | Interleukin-1 formulation | |
| JPH0761955B2 (en) | Lyophilized hepatitis A vaccine | |
| TH2141A (en) | ||
| AU636653B2 (en) | Stabilized leukocyte-interferons | |
| JPH031290B2 (en) | ||
| Ishihara et al. | Pathological characteristics of acute exacerbation of Hashimoto's thyroiditis-Serial changes in a patient with repeated episodes | |
| TH3859A (en) | ||
| Norrby et al. | Humoral immunity to canine distemper after immunization of dogs with inactivated and live measles virus | |
| JPS57118790A (en) | Freeze-dried substance containing beta-d-galactosidase | |
| Ashe et al. | Inapparent herpes simplex virus infection in inoculated rabbits | |
| Rollins et al. | The Influence of Altered Viral Virulence on the Response of Host Serum Alpha₂ Glycoglobulins | |
| KR930004600B1 (en) | Method for preparing γ-interferon composition | |
| RU2024121592A (en) | Lyophilized composition containing a fusion protein including α-galactosidase A |